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Background: Intensity modulated radiotherapy is an efficient radiotherapy technique to increase dose in target
volumes and decrease irradiation dose in organs at risk. This last objective is mainly relevant in children. However,
previous results suggested that IMRT could increase low dose, factor of risk for secondary radiation induced cancer.
This study was performed to compare dose distributions with 3D-radiotherapy (3D-RT) and IMRT with tomotherapy
(HT) in children with neuroblastoma. Seven children with neuroblastoma were irradiated. Treatment plans were
calculated for 3D-RT, and for HT. For the volume of interest, the PTV-V95% and conformity index were calculated.
Dose constraints of all the organs at risk and integral dose were compared.
Results: The conformity index was statistically better for HT than for 3D-RT. PTV-V95% constraint was reached in 6
cases with HT compared to 2 cases with 3D-RT. For the ipsilateral kidney of the tumor, the V12 Gy constraint was
reached for 3 patients with both methods. The values were lower with HT than with 3D-RT in two cases and higher
in one case. The threshold was not reached for one patient with either technique, but the value was lower with HT
than with 3D-RT. For the contralateral kidney of the tumors, the V12 Gy constraint was reached for all patients with
both methods. The values were lower with HT than with 3D-RT in 5 of 7 children, equal in one patient and higher
in one patient. The organ-at-risk volumes receiving low doses were significantly lower with 3D-RT but larger for the
highest doses, compared to those irradiated with HT. The integral doses were not different.
Conclusions: IMRT with HT allows a better conformity treatment, a more frequently acceptable PTV-V95% than
3D-RT and, concomitantly, a better shielding of the kidneys. The integral doses are comparable between both
techniques but consideration of differences in dose distribution between the two techniques, for the organs at risk,
has to be taken in account when validating treatment.
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The treatment of children with malignant tumors poses a
great challenge to a pediatric oncology team. The standard
management of neuroblastoma includes chemotherapy,
surgery and radiotherapy. Irradiation doses are low, and a
recent study from the Children’s Cancer Group showed a
dose–response relationship with respect to local control,
in which 20 Gy delivered to the primary site, had a better
locoregional control rate than 10 Gy [1]. Children’s tissues
are radiosensitive because they are still growing, and
radiation treatment of neuroblastoma has been ques-
tioned. Because cancers in children are always chemosen-
sitive, recent therapeutic protocols have attempted to
decrease the use of radiotherapy according different ways
[2-5]. Deleterious late effects can affect mainly musculo-
skeletal retardation due to the irradiation of the vertebrae
and renal failure because of the proximity of the contrala-
teral kidney and also of the ipsilateral kidney, if not
removed with the tumor [6]. These late effects could have
important consequences in terms of quality of life. Add-
itionally, there is also the possibility of a second primary
malignancy occurring in the field of irradiation or in other
sites receiving small or large doses [7,8].
IMRT allows increased doses in a tumor volume in an
attempt to improve disease control and allow decreasing
doses in organs at risk to reduce complications or side
effects and, consequently, to improve the quality of life.
However, in pediatric treatment, IMRT raises some ques-
tions regarding dose distribution. Indeed, IMRT decreases
the volume receiving the highest doses but increases the
irradiated volumes at low doses because of the multiplica-
tion of fields creating a dose bath effect. Integral dose
could allow integration of all of the dose scales and the
generation of a global value of risk, but it remains to be
evaluated clearly and fully.
In an attempt to provide a definitive answer, we pro-
posed to theoretically compare the dosimetry used in
seven children treated with irradiation for neuroblastoma.
Dose distribution was calculated for 3D-radiotherapy
delivered by linear accelerator (3R-RT) and for inten-
sity modulated radiotherapy (IMRT) delivered by helical
tomotherapy (HT).Methods
Seven children aged from 21 months to 5 years were
included in this study. The disease was diagnosed because
of abdominal pain in six cases and long-term fever in one
case. Staging of all children was performed, including
abdominal and lung CT scans, MIBG scans and catechol-
amine dosages, before treatment. At the end of the sta-
ging, all children had an International Neuroblastoma
Staging System (INSS) score of 4 because of metastasis in
the bone marrow for 5 cases, in the bones for 3 cases andin the abdominal nodes for 3 cases, with pleural effusion
ac-counting for one case (Table 1).
Chemotherapy was performed following the HNRBL1
protocol, which included different steps of the asso-
ciated drugs (cisplatin, vincristine, carboplatin, etopo-
side and cyclophosphamide) given in a rapid delivery
schedule [9,10] (Table 1). After chemotherapy, surgical
resection was planned. Tumor removal included homo-
lateral left nephrectomy in two cases and right nephrec-
tomy in one case because partial nephrectomy was
infeasible. Surgical resection was considered to be
microscopically complete in 6 children and incomplete
with probable viable tumor cells in the other case. After
surgery, all patients were treated with high-dose chemo-
therapy, followed by autologous stem-cell transplant-
ation. Five children were irradiated under complete
anesthesia. Children were treated with tomotherapy.
The protocol was approved by local ethics committee.
Research was performed in compliance with the Hel-
sinki declaration. Children’ parents signed consent after
complete and clear information.
All patients underwent CT simulation using a General
Electric (GE) light-speed scanner (General Electric,
Milwaukee, WI). Four-D CT was not assessed for these
patients. The planning volume from the midthorax to the
lower portion of the pelvis was scanned in 2.5-mm incre-
ments without contrast injection. Children were treated in
the supine position in vacuum cradles for immobilization.
The beam-on time varied from 142 to 412 seconds, rela-
tively long compared with conventional techniques. The
MV-CT imaging before treatment can also quite lengthy,
requiring up to 10 minutes of imaging time per acquisi-
tion, fusion and correction of positioning. However, we
previously controlled in the first children treated with
tomotherapy the absence of intrafraction motion by a new
positioning CT at the end of treatment. This question of
beam-on time was not analyzed in our study and could be
raise in concerns about intrafraction motion. Volumes were
delineated with Focal (Computerized Medical System, St.
Louis, MO, USA). The targeted volume was the initial
tumor site that represented the CTV. This volume was
delineated according to the initial diagnostic CT scan. The
PTV was automatically delineated by adding a 5-10-mm
3D margin. The delineated organs at risk were the kidneys,
vertebrae, liver, spinal cord, spleen, stomach and pelvic
bone. The entire spinal cord was delineated. Dosimetries
were calculated using Xio (Elekta AB, Stockholm, Sweden)
and tomotherapy planning systems (Tomotherapy Incorpo-
rated, Madison, WI, USA). The dosimetric comparison was
performed with Artiview (Aquilab, Lille, France). Radiother-
apy was delivered at 21 Gy in 14 fractions for 5 days a week.
The PTV was planned to receive at least 95% of the pre-
scribed dose. Three-D-RT dosimetry was performed with
two opposed, parallel antero-posterior or oblique-anterior
Table 1 Children characteristics
# Age Gender Localization amplified
Nmyc














1 2.5 yr F Right Yes IV Abdominal nodes
Medullar
Yes Yes Initial tumor site 5 mm 21 Gy 1.5 Gy HNRBL1 yes
2 3 yr F Left Yes IV Abdominal nodes
Medullar Bone
Yes Yes Initial tumor site 5 mm 21 Gy 1.5 Gy HNRBL1 Yes
3 5 yr M Left Yes IV Pleural No Yes Initial tumor site 5–10 mm 21 Gy 1.5 Gy HNRBL1 Yes
4 3.5 yr M Left No IV Bone No Yes Initial tumor site 5–10 mm 21 Gy 1.5 Gy HNRBL1 Yes
5 21 months F Left No IV Medullar Bone No Yes Initial tumor site
T11-12 Sacrum
5–10 mm 21 Gy 1.5 Gy HNRBL1 Yes
6 3 yr M Left ? IV Abdominal nodes
Medullar
No No Initial tumor site 5–10 mm 21 Gy 1.5 Gy HNRBL1 Yes
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with 6 and/or 25 MV beams (Figure 1A). For IMRT with
tomotherapy, the field width, pitch and modulation factors
usually used for treatment planning and optimization were
2.5 cm, 0.287 and 2.5, respectively (Figure 1B). The dosi-
metry was performed in regards of some organs at risk con-
straints. The volume of each kidney that received 12 Gy
(V12 Gy) was limited to 20% in cases in which both kidneys
were preserved and to <15% if only one kidney had been
preserved [6]. Because of the risk of a lack of homogeneous
vertebrae growth if a uniform dose was not delivered to this
bone, a uniform dose into all the vertebrae proximal to the
targeted volume was required, i.e., at least 80% of each irra-
diated vertebrae had to receive 80% of the prescribed dose.
In all cases, vertebrae were included into CTV as they were
in contact with or near the tumor. For the liver, no limit
was proposed because a mean dose of 25 Gy into the total
organ was considered acceptable [11] although some
authors have advocated delivering a mean dose below 20
Gy when a combination of busulfan and melphalan is used
as the protocol HNRBL1.
To attempt to obtain the best compromise we orga-
nized the constraints as following: V12 in the contralateral
kidney, coverage of PTV, homogeneity in the vertebrae
and V12 in the ipsilateral kidney.Child 1 -A 
Child 1 - B 
Figure 1 Dose distribution 3D-RT (A) and HT (B) for children with obl
Red color: at least 95%, yellow: a least 90%; green at least 50% and blue at
shown because this dose is believed to be important for the secondary radStatistics
For all organs, dose-volume histograms were calculated.
For all organs at risk, the average doses were compared.
Furthermore, we compared different factors for the target
volume [12,13]: PTV-V95% corresponds to the percentage
of the PTV receiving at least 95% of the dose, according to
the ICRU 50, and the conformity index (RIV/PTV) corre-
sponded to the ratio between the reference isodose volume
(RIV) and the PTV. We also calculated and compared the
integral dose, which is the mean dose delivered to the total
body minus the PTV (mean dose) / (noninvaded body vol-
ume—PTV). We also compared dose distributions in the
organs at risk end for the total body.
Values were compared using the two-tailed nonpara-
metric Wilcoxon test. Statistical analysis was performed
using Statview 5.1 software (SAS industries).
Results
Targeted volume
PTV-V95%: The mean values were 95% (86.9–97.9) for
HTand 88.7% (76.4–98.8) for 3D-RT. The difference in dis-
tribution was not statistically different (p=0.3). This con-
straint was reached in 6 children on 7 with HT, compared
to only 2 cases with 3D-RT (p< 0.05). In the child for
whom the V95 constraint was not reached by HT, the valueChild 2 – A 
Child 2 - B 
ique fields for RT-3D (child 1) and antero-posterior fields (child 2).
least 10% of the prescribed dose (~2 Gy). The 2-Gy isodose was
iation-induced cancer risks.
Table 2 Average mean value of the series
HT 3D-RT
Average mean value Intervals Average mean value Intervals
Homolateral kidney 6.8 Gy 3.4–14.3 8.2 Gy 3.5–17.7
Controlateral kidney 3.3 Gy 0.6–6.0 2.2 Gy 0.5–3.4
Vertebrae 11.5 Gy 4.4–18.3 11.3 Gy 5.4–18.6
Sacroiliac joints 4.7 Gy 0.03–20.8 3.6 Gy 0.00–20.6
Liver 6.2 Gy 4.6–9.8 5.4 Gy 1.5–10.6
Spleen 8.1 Gy 3.9–14.3 9.8 Gy 0.3–21.4
Stomach 11.0 Gy 6.5–15.5 12,2 Gy 3.8–21
V0.150 Gy/fraction 47.3% 38.8–65.1 32.2% 27.4–39.0
Integral dose 20.99 Gy/L 9.5–32.6 20.92 Gy/L 11.1–42.3
V95% 95% 86.9–97.9 88.7% 76.4–98.8
Conformity index 1.57 1.0–2.22 2.93 1.97–3.79
HT : helical tomotherapy ; 3D-RT : 3D radiotherapy.
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and 3)
Conformity index: The mean values were 1.57 (1–2.22)
for HT and 2.93 (1.97–3.79) for 3D-RT. The difference in
the distribution of the mean values was statistically signifi-
cant (p=0.02). The values were higher with 3D-RT in 6
cases, with a 3D-RT/HT mean ratio of 2.26 (1.37–3.79). In
one case, the values were lower for 3D-RT than for HT, i.e.,
1.97 and 2.1, respectively.Organs at risk
Irradiation of the homolateral kidney of the tumor or bed
site
This topic concerned 4 children. The mean average dose
was 6.8 Gy (3.4–14.3) for HT and 8.2 Gy (3.5–17.7) for 3D-
RT. The V12 Gy constraint was reached for 3 patients using
both methods. The values were lower with HT than with
3D-RT in two cases and higher in one case but below the
threshold. The threshold was not reached for one patient
with both techniques, but the value was lower for HT thanTable 3 Patients’V95%, conformity index, V12 Gy (%) for kidney
and 3D-Radiotherapy dosimetry
V95% Conformityindex Controlateral kidne
HT 3D-RT HT 3D-RT HT 3
Patient 1 96.7% 94.5% 2.22 3.52 1.8%
Patient 2 95.8% 81.0% 1.46 2.00 11.8%
Patient 3 97.9% 76.4% 1.89 3.74 1.4%
Patient 4 95.4% 97.1% 1.31 3.38 0%
Patient 5 96.1% 83.3% 2.1 1.97 0.6%
Patient 6 96.2% 98.8% 1.00 3.79 0.3%
Patient 7 86.9% 89.9% 1.02 2.11 0%
HT : helical tomotherapy ; 3D-RT : 3D radiotherapy.for 3D-RT. The mean V12 Gy was 22.4% (4.6–57.8) for HT
and 39.9% (15.4–100) for 3D-RT. The difference in the dis-
tribution was not statistically different (Tables 2 and 3).Irradiation of the kidney contralateral to the tumor bed site
This measurement concerned 7 children. The mean aver-
age doses were 3.3 Gy (0.6–6.0) for HT and 2.2 Gy (0.5–
3.4) for 3D-RT. The mean V12 Gy was 2.3% (0–11.8) for HT
and 2.8% (0–8.6) for 3D-RT. The V12 constraint was
reached for all patients with both methods. The values were
lower with HT than with 3D-RT in 5 of 7 children, equal
for one patient (but 0% for child #4) and higher with HT
than with 3R-RT in one patient (child #2), but the values
were below the threshold. No differences in the distribution
were statistically significant.Irradiation of other organs at risk
The mean average doses are reported in Table 2. The dif-
ferences in the distribution were not statistically signifi-
cant with both techniques.s and integral doses according to helical tomotherapy
y V12 Gy Homolateral kidney V12 Gy Integral dose(Gy/mL)
D-RT HT 3D-RT HT 3D-RT
7.6% - - 16.1 16.7
0.1% - - 32.6 25.5
2.4% 57.8% 100% 30.9 42.3
0% 9.6% 20.8% 18.4 18.7
1.0% 17.5% 15.4% 20.4 12.9
8.6% 4.6% 23.3% 9.5 11.1
0.2% - - 19.0 19.3
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The liver volumes receiving doses from 1 to 5 Gy were sig-
nificantly lower for 3D-RT (p=0.018). Between 6 and 8 Gy
and at 21 Gy the volume distributions were not significantly
different. Between 9 and 20 Gy, the liver volumes were sig-
nificantly lower for HT (p=0.0425–0.028). Curves intersect
at a dose of 7 Gy. The spleen volume receiving doses from 1
to 3 Gy was significantly lower for 3D-RT (p=0.0431–
0.0464). Between 4 and 11 Gy, the volume distributions were
not significantly different. Between 12 and 21 Gy, the spleen
volumes were significantly lower for HT (p=0.0425–0.028).
Curves intersect at a dose of 8 Gy. The vertebrae volumes
receiving doses from 1 to 20 Gy were not significantly differ-
ent. At 21 Gy, the vertebrae volume was significantly lower
for HT (p=0.028). Curves intersect at a dose of 12 and 13
Gy. The pelvis bone volumes receiving doses from 1 to 21
Gy were not significantly different. The spleen volume re-
ceiving doses from 1 to 2 Gy was significantly lower for 3D-
RT (p=0.028–0.042). Between 3 and 8 Gy and between 18
and 21 Gy, the volume distributions were not significantly
different. Between 9 and 17 Gy, the spleen volumes were sig-
nificantly lower for HT (p=0.0277–0.0464). Curves intersect
at a dose of 6.5 Gy. The contralateral kidney volumes receiv-
ing doses from 1 to 3 Gy were significantly lower for 3D-RT
(p=0.0431–0.0464). Between 4 and 11 Gy, the volume dis-
tributions were not significantly different. Between 12 and
21 Gy, the spleen volumes were significantly lower for HT
(p=0.0425–0.028). Curves intersect at a dose of 8 Gy. The
stomach volumes receiving doses from 2 and 3 Gy were sig-
nificantly lower for 3D-RT (p=0.0464). At 1 Gy, between 4
and 12 Gy and at 21 Gy, the volume distributions were not
significantly different. Between 13 and 20 Gy, the spleen
volumes were significantly lower for HT (p=0.018–0.0425).
Curves intersect at a dose of 8 Gy. The total body volumes
receiving doses from 1 to 5 Gy were significantly lower for
3D-RT (p=0.018–0.028). Between 6 and 9 Gy, the volume
distributions were not significantly different. Between 10 and
20 Gy, the total body volumes were significantly lower for
HT (p=0.0425–0.018). Curves intersect at a dose of 7 Gy
(Figure 2).Volume receiving a dose of 0.150 Gy per fraction
The mean percentages of the volume receiving less than
0.150 Gy per fraction were 47.3% (38.8–65.1) for HT and
32.2% (27.4–39.0) for 3D-RT. The percentage differences
were statistically significant (p=0.018) (Table 3).Integral dose
The mean integral doses were 20.99 Gy/L (9.5–32.6) for
HT and 20.92 Gy/L (11.1–42.3) for 3D-RT. The difference
in the distribution of the values was not statistically signifi-
cant (p=0.5) (Tables 2 and 3).In total—combination of constraints
If we consider the seven children who were relevant
for the V95% and contralateral kidney constraint, six (all
except child #7) reached below-threshold values with
HT, as compared to two children with 3D-RT (#4 and
#6) (p< 0.05). If we consider the four children who
were relevant for the V95% contralateral and ipsilateral
kidney constraints, 3 (#4–6) reached values below the
constraints with HT, as compared to no children with
3D-RT (p< 0.05).
Discussion
IMRT is an elegant technique for the treatment of children
and allows a reduction of the high dose of radiation deliv-
ered to the tissues surrounding a tumor. To our knowledge,
this article is the first publication to describe a dose com-
parison between tomotherapy and 3D-RT in neuroblast-
oma and is the third to compare IMRT and 3D-RT [14,15].
For pediatric irradiation, three goals have to be pursued:
tumor control, avoidance of complications or sequellae and
a decrease of the secondary radiation-induced cancer risk.
Because the contralateral kidney was close to the surgi-
cal bed and there was a need to deliver a homogeneous
dose in the vertebrae, the PTV-V95% constraint remains
challenging with 3D-RT. In this series the PTV-V95% con-
straint was achieved in 6 cases on 7 with HT compared to
2 cases only with 3D-RT. Furthermore, to obtain the best
dose distribution with 3D-RT, the irradiated volumes are
high, as demonstrated by the conformity index, which is
approximately two-fold greater with 3D-RT compared to
HT, (1.2 vs 2.9). Thus, HT achieved the first goal of
pediatric irradiation, i.e., the possibility of better local con-
trol by improving the dose-to-tumor distribution. Con-
formity was already improved with other IMRT technique
[15]. Although the risk of early or late complications at
this dose is low, dose distribution to different organs have
to be discussed, i.e., the kidneys, vertebrae. Because these
young children also receive cisplatin, a well-known
nephrotoxic agent, minimizing the radiotherapy dose to
both kidneys is important because it may translate to less
organ dysfunction. Differentiation has to be made between
children with one or two remaining kidneys.
In cases in which the ipsilateral kidney had been
removed, the shielding of the contralateral kidney must be
strict. In our study, the overall values were very low and al-
ways below the dose thresholds for both radiotherapy tech-
niques, and we did not observe statistically significant
differences in the mean doses and V12 values between the
two techniques. However, the V12 values were 18% lower
for HT than for RT3D. In contrast, the average values were
50% higher for HT than for RT3D, i.e., 3.3 Gy and 2.2 Gy,
respectively. This increasing of the dose with IMRT was
described by Shaffer et al, but our figures were lower than
those reported by these authors. The reason is probably
A : liver
Dose 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
« p SN50.0<SN50.0<»
B : spleen
Dose 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
« p 50.0<SN50.0<»
C : vertebrae
Dose 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
« p 50.0<SN»
D : iliac bone
Dose 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
« p SN»
E : contralateral kidney
Dose 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
« p SN50.0<SN50.0<»
F : stomach
Dose 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
« p SN50.0<SN50.0<SN»
F : total body
Dose (Gy) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
« p » 0.018to 0.028 NS 0.018to 0.0425 NS
Figure 2 Curves (IMRT TM—IMRT by tomothérapie and RT-3D) of mean organ or total body volumes irradiated at dose between 1 to 21
Gy. Statistical signification dose by dose on table under curve.
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our series [15].
For the cases in which the homolateral kidney had been
preserved, the main advantage of the IMRT could be its
shielding of part of the remaining ipsilateral kidney, thus
decreasing its risk of postirradiation involution. For the kid-
ney ipsilateral to the tumor, the mean average dose was
reduced by 17% with HT compared to 3D-RT, and the
mean V12 Gy was reduced by 43%. Some explanations for
the lack of a more striking difference in shielding with HT
include the following: (1) the need to irradiate vertebrae athigher doses than could be administered to avoid inhomo-
geneous growth of the bone and increase the dose to the
contralateral kidney; and (2) technical reasons related to
the tomotherapy system. To obtain a homogeneous dose in
the target volume (PTV), the multileaf is opened to one size
of the collimator width before and after the appearance of
the target volume in the beam. This opening is total, i.e.,
not progressive. Thus, because we used 2.5 cm of collima-
tor width, the size taken into account for irradiation was
increased by 2.5 cm below and above the PTV in the cra-
nio-caudal direction. Thus, compared to 3D-RT, the total
Beneyton et al. BMC Medical Physics 2012, 12:2 Page 8 of 9
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Another point can be discussed is the motion of kidneys
according to the respiratory control. A recent study con-
cluded that the renal motion is highly correlated to age and
weight of the child and diaphragmatic motion. However,
authors concluded that, because of the low absolute magni-
tude of renal motion, the role of respiratory gating in
younger children is limited [16].
Skeletal problems when using IMRT can be minimized
by including adjacent vertebrae into the PTV. In a large
series of children treated for Wilm’s tumor, Paulino et al
differentiated children according delivered dose. RT dose
was 1000–1200 cGy (Group A) in 12, 1201–2399 cGy
(Group B) in 11, and 2400–4000 cGy (Group C) in 19. The
10- and 15-year actuarial incidences of scoliosis for Group
A and B patients were 37.7±12.4% and 37.7±12.4%,
whereas for Group C patients the incidences were
65.8± 12.0% and 74.4± 11.7% (p=0.03) [17]. Although con-
ventional 3D-RT delivers a somewhat homogeneous dose
to the spine, HT with inclusion of the adjacent spine in the
PTV offers the same homogeneous dose distribution, with
no difference in mean doses. However, with the same dose
distribution, the kidneys were better shielded, and the target
volume, i.e., PTV, was better covered. Our conclusions are
comparable with the previous comparison of 6 children
published by Paulino et al [14] and cases analyzed by
Shaffer et al; [15]. This is in accordance with Paulino et al
study which advocated the inclusion of vertebrae in the
CTV, in order to reduce dose heterogeneity and therefore
reduce the incidence of skeletal growth deformities [14].
Even if Plowman et al attempt to demonstrate the contrary
and advocate an increasing of integral dose by inclusion of
vertebrae in the CTV, we cannot prove this assertion [18].
The goal of preventing radiation damage is crucial, par-
ticularly in children less than 3 year-old. However, radi-
ation-induced carcinogenesis is not simply the result of
mutations of stem cells. Several factors can confuse radi-
ation causality, and sporadic cancer, genetic factors, lifestyle
(including exogenous factors) and radiological irradiation
are largely used for follow-up [8]. The role of the delivered
dose is controversial. Proponents of a linear (no-threshold)
relationship believe that the carcinogenic effect of any dose
can be assessed by this relationship, while others claim that
the role of low doses is underestimated because they do not
take into account bystander effects. Conversely, radiobiolo-
gists and radiation oncologists have concluded that clinical
experiences have not confirmed these allegations, and
moreover that these low doses could induce an adaptive re-
sponse in cells by stimulating the efficiency of DNA-repair
capacities. In this study, body volumes receiving 1 to 5 Gy
were significantly larger with HT than with 3D-RT. How-
ever, volumes receiving 7 and 10 Gy were equal between
both techniques, and volumes receiving doses higher than
10 Gy were significantly smaller with HT than with 3D-RT.The difference of dose distribution is clearly related to the
dose for all organs, with larger volumes irradiated at low
dose with IMRT and larger volumes irradiated a high dose
with RT-3D. The pathology type of the secondary tumors
probably depends on the dose; The results already pub-
lished based on this population demonstrated that the mag-
nitude of the radiation dose received at the site of origin
increased the risk of an second malignant cancer [19].
Thus, sarcoma occurs in the tissues receiving the highest
dose [7,20]. Dose levels at which SMN are most likely to
occur have not yet been clearly established. Kirova et al.
[21] showed that most reported cases of radiation-induced
sarcomas after breast irradiation occurred at sites that had
received doses of 60–80 Gy, with a minimal dose of 10 Gy.
Dörr and Herrmann [22] reported that the majority of sec-
ond tumors occurred at sites that had received <6 Gy and
were located within the margin region of the planning tar-
get volume (PTV), defined as the volume from 2.5 cm in-
side to 5 cm outside the margin of the PTV.
In a report on second malignancy in the United States,
Wilms et al. showed that it is important to reduce the
volumes receiving 20 Gy or more to decrease the risk of
secondary cancers [23]. In our series, even if prescription
doses were relatively low, i.e. 21 Gy, we show that HT
should provide this opportunity by the decrease of the CI
from 2.97 with 3D-RT to 1.57 with HT. Having demon-
strated that the majority of second cancer had developed
within volumes exposed to intermediate doses, Diallo et al
suggest that tomotherapy and linear accelerator IMRT may
increase the risk of second cancers by increasing the vol-
ume of intermediate dose regions. These results should be
taken into account in the RT strategy [7].
It should be remembered that the issue of radiation-
induced carcinogenesis is not without controversies. In
particular, the phenomenon of radiation hormesis at low-
radiation doses has attracted increasing attention [24].
Radiation hormesis is considered to be an adaptive re-
sponse to the external stress of radiation exposure and is
manifested in several cell lines in the form of reduced
chromosomal aberrations and increased longevity. Extrapo-
lating risk of radiation-induced carcinogenesis is an uncer-
tain exercise. Data on radiation carcinogenesis are mainly
derived from retrospective studies, with variable patient
populations exposed to variable radiation doses whose dos-
imetry is often uncertain. In addition, a heightened risk of
second malignancies may exist in these patients. In an ex-
tensive review of the literature, Suit et al. concluded that
the experimentally observed heterogeneity in secondary
induced-cancer risk indicates a large genetic role in deter-
mination of risk in the individual [20]. Furthermore, due to
the quite large and undefined heterogeneity in the patient
populations studied, no precise quantification of the risk of
radiation-induced secondary cancer is available at present
[20]. Most of the second cancer arising from irradiated
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cancers. Even if consequences in terms of second cancer
are not yet a high-priority issue for radiation oncologists
(comparing to the control of the cancer and the survival of
patient), lowering the distant doses remains an important
public health issue and a major challenge for RT in the fu-
ture. A better understanding of dose distributions, inducible
second cancer, for each organ, is necessary to perform dos-
imetry with real dose constraints to protect the develop-
ment of second cancers. Also, prudence principle is
required. In this goal, radiation oncologists are able to dem-
onstrate some advantages of IMRTcompared to 3D-RT.
Conclusions
In conclusion, for children developing central neuroblast-
oma, IMRT with HT is a more efficient radiation technique
than 3D-RT to ameliorate the dose coverage of the target
volumes and to decrease the dose into the kidneys. Further-
more, the volumes receiving low doses are higher with HT,
the volumes receiving the highest doses are lower with HT
than with 3D-RT even if the integral doses were compar-
able between both techniques, and even if.
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